| __timestamp | ADMA Biologics, Inc. | Teva Pharmaceutical Industries Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 9216000000 |
| Thursday, January 1, 2015 | 4311461 | 8296000000 |
| Friday, January 1, 2016 | 6360761 | 10044000000 |
| Sunday, January 1, 2017 | 29164321 | 11560000000 |
| Monday, January 1, 2018 | 42194635 | 10558000000 |
| Tuesday, January 1, 2019 | 39504238 | 9351000000 |
| Wednesday, January 1, 2020 | 61291426 | 8933000000 |
| Friday, January 1, 2021 | 79769341 | 8284000000 |
| Saturday, January 1, 2022 | 118814535 | 7952000000 |
| Sunday, January 1, 2023 | 169273000 | 8200000000 |
| Monday, January 1, 2024 | 8480000000 |
Cracking the code
In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. From 2014 to 2023, Teva Pharmaceutical Industries Limited and ADMA Biologics, Inc. have shown contrasting trends in their cost of revenue. Teva, a global leader, saw a decline of approximately 14% in its cost of revenue, from $9.2 billion in 2014 to $8.2 billion in 2023. This reduction reflects strategic cost management amidst market challenges. Conversely, ADMA Biologics, a niche player, experienced a staggering 4,400% increase, from $3.7 million to $169 million over the same period. This surge highlights ADMA's aggressive expansion and scaling efforts. These insights underscore the diverse strategies employed by pharmaceutical companies to navigate financial landscapes. As the industry continues to innovate, monitoring these financial metrics will be key to understanding future market dynamics.
AbbVie Inc. vs Teva Pharmaceutical Industries Limited: Efficiency in Cost of Revenue Explored
AstraZeneca PLC vs Teva Pharmaceutical Industries Limited: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Vertex Pharmaceuticals Incorporated and Teva Pharmaceutical Industries Limited's Expenses
Cost Insights: Breaking Down Teva Pharmaceutical Industries Limited and Intra-Cellular Therapies, Inc.'s Expenses
Cost of Revenue: Key Insights for Teva Pharmaceutical Industries Limited and Halozyme Therapeutics, Inc.
Breaking Down Revenue Trends: Teva Pharmaceutical Industries Limited vs ADMA Biologics, Inc.
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs Amneal Pharmaceuticals, Inc.
Cost of Revenue Comparison: Teva Pharmaceutical Industries Limited vs HUTCHMED (China) Limited
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Dyne Therapeutics, Inc.
BeiGene, Ltd. vs ADMA Biologics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Exelixis, Inc. and ADMA Biologics, Inc.
Cost of Revenue: Key Insights for ADMA Biologics, Inc. and Celldex Therapeutics, Inc.